Mergers & Acquisitions Mergers & Acquisitions

Grail, like Illumina, challenges EU’s interim measures in court

American cancer-testing company Grail last week lodged a case in the EU’s General Court challenging the interim measures the European Commission put in place after biotech company Illumina closed the acquisition prior to obtaining EU approval, MLex has learned.

The application was made on Jan. 11, according to an update to the court’s

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News